Impact of different therapeutic regimen on prognosis in CEBPAbZIP-infacute myeloid leukemia(摘要号:4274) 报告时间: 2024年12月9日,星期一,下午6:00至8:00(美国西部时间) 2024年12月10日,星期二,上午10:00至12:00(北京时间)...
[3] Zeng M, Chen K, Tian X, et al. Clinical characteristics and prognosis analysis of patients with de novo ASXL1-mutated AML treated with the C-HUNAN-AML-15 protocol: A multicenter study by the South China Pediatric AML...
Impact of different therapeutic regimen on prognosis in CEBPAbZIP-infacute myeloid leukemia(摘要号:4274) 报告时间: 2024年12月9日,星期一,下午6:00至8:00(美国西部时间) 2024年12月10日,星期二,上午10:00至12:00(北京时间) 第一作者:潘佳佳 通讯作者:王华锋、金洁 研究背景 CEBPA突变是急性髓系白血病...
For Leukemia Awareness Month, Salman Fazal, MD, and Tibor Kovacsovics, MD, discussed the importance of biomarker testing and targeting in diagnosis, prognosis, and treatment of acute myeloid leukemia. Read More Quizartinib Improves OS in Multiple FLT3-ITD+ AML Subgroups ...
Additionally, the fairly good sensitivity, specificity, and clinical relevance of miR-182 promoter methylation discovered in our study make it a valuable tool for identifying and monitoring methylation changes associated with prognosis. Therefore, we offer a rapid and quantitative method to predict the ...
Notably, activating mutations occurring in the FLT3 gene, which impact prognosis upon conventional systemic treatment [20], do not affect FLYSYN binding, allowing for application irrespective of FLT3 mutational status. Overall, there is an increasing interest in targeting FLT3 for immunotherapy not ...
et al. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML. Leukemia 25, 874–877 (2011). Article CAS PubMed Google ...
299 Given the poor prognosis of secondary AML evolving from prior MDS and the limited knowledge of mutations that occur during transformation, we set out to comprehensively discover gene mutations that occur during MDS to AML transformation. To achieve this goal, we performed whole genome sequencing...
Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol. 2022;40(8):855-865. doi:10.1200/JCO.21.01546 Othman J, Tiong IS, Mokretar K, et al. Molecular MRD assessment is strongly prognostic in patients with NPM...
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma J. Clin. Oncol., 36 (2018), pp. 2267-2280 CrossrefView in ScopusGoogle Scholar 11 D.W. Lee, J.N. Kochenderfer, M. Stetler-Stevenso...